MYRANOVA Trademark

Trademark Overview


On Thursday, July 17, 2025, a trademark application was filed for MYRANOVA with the United States Patent and Trademark Office. The USPTO has given the MYRANOVA trademark a serial number of 99288313. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, January 5, 2026. This trademark is owned by Medytox Inc.. The MYRANOVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical agents affecting sensory organs; muscle relaxants; pharmaceutical agents affecting peripheral nervous system; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; pharmacological preparations for skin care; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; injectable dermal fillers; pharmaceutical preparat...
myranova

General Information


Serial Number99288313
Word MarkMYRANOVA
Filing DateThursday, July 17, 2025
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateMonday, January 5, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical agents affecting sensory organs; muscle relaxants; pharmaceutical agents affecting peripheral nervous system; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; pharmacological preparations for skin care; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; injectable dermal fillers; pharmaceutical preparations acting on the central nervous system; pain relief medication; dermatological pharmaceutical products.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 17, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMedytox Inc.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressChungcheongbuk-do 28126
KR

Trademark Events


Event DateEvent Description
Thursday, July 17, 2025NEW APPLICATION ENTERED
Thursday, July 17, 2025APPLICATION FILING RECEIPT MAILED
Thursday, July 17, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 4, 2025ASSIGNED TO EXAMINER
Thursday, December 4, 2025NON-FINAL ACTION WRITTEN
Thursday, December 4, 2025NON-FINAL ACTION E-MAILED
Thursday, December 4, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 5, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 5, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 5, 2026TEAS/EMAIL CORRESPONDENCE ENTERED